Virax Biolabs Group Ltd (NASDAQ: VRAX) saw its shares surge by approximately 45% on Wednesday after announcing a partnership with a leading supplier of Mpox detection kits. The partnership grants Virax the rights to sell RT-PCR tests for Mpox across more than a dozen European countries and several Middle Eastern nations. However, the financial terms of the agreement were not disclosed. Following this news, Virax’s stock is now trading at roughly 10 times its value from late April. Why the Mpox tests are important for Virax stockThis development is significant because expanding the sale of Mpox…